SPA
TXG icon

Sherbrooke Park Advisers’s 10x Genomics TXG Stock Holding History

Sherbrooke Park Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,142
Closed -$175K – 719
2025
Q2 		$175K Buy
+15,142
New +$138K 0.08% 412
2025
Q1 		– Sell
-33,311
Closed -$478K – 945
2024
Q4 		$478K Buy
33,311
+3,162
+10% +$49.9K 0.15% 228
2024
Q3 		$681K Sell
30,149
-10,938
-27% -$226K 0.16% 199
2024
Q2 		$799K Buy
41,087
+20,401
+99% +$534K 0.14% 234
2024
Q1 		$776K Buy
+20,686
New +$909K 0.15% 218

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sherbrooke Park Advisers's TXG Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of 10x Genomics (TXG) in Q3 2025, closing a stake of 15,142 shares — an estimated $175K sold.

Sherbrooke Park Advisers first reported a position in TXG in Q1 2024 and held it in 5 quarters. The position peaked at $799K in Q2 2024. 317 funds tracked by Wall St. Rank hold TXG as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining 10x Genomics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 15,142 10x Genomics shares in Q3 2025, an estimated $175K.
  • Sherbrooke Park Advisers first reported a position in 10x Genomics in Q1 2024 and held it in 5 quarters.
  • Sherbrooke Park Advisers's 10x Genomics position peaked at $799K in Q2 2024.
  • 317 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.